Trial Success for MAR001 Phase 2a and New Acromegaly Program Unveiled by Marea Therapeutics
Trial Success for MAR001 Phase 2a and New Acromegaly Program Unveiled by Marea Therapeutics Marea Therapeutics, a clinical-stage biotechnology company focused on developing next-generation treatments for cardio-endocrine diseases, shared important…